← Back to Investors

Sunstone Life Science Ventures

Sunstone Life Science Ventures is a leading Nordic venture capital firm focused exclusively on life sciences investments. The firm invests in innovative European biotechnology and medical technology companies across therapeutics, diagnostics, and medical devices.

Location
Copenhagen, Denmark
Founded
2007
AUM
€600M+
Investment Range
€2M - €20M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c

Investment Thesis

Sunstone invests in European life sciences companies with breakthrough science and strong intellectual property. They focus on companies developing novel therapeutics, diagnostics, and medical technologies that can address significant unmet medical needs. The firm brings deep scientific expertise and extensive networks to support portfolio company growth.

Team

Partners / Managing Directors

  • Søren Møller - Managing Partner
  • Christian Elling, PhD - Partner
  • Nikolaj Høyer-Hansen, PhD - Partner

Other Key Team Members

  • Steen Lomholt-Thomsen - Partner
  • Scientific Advisory Board - Leading life sciences experts

Focus Areas

  • Oncology
  • Immunology
  • Rare Diseases
  • Central Nervous System
  • Medical Devices
  • Diagnostics
  • Drug Delivery

Notable Portfolio Companies

  • Galecto - Galectin therapeutics for fibrosis (IPO 2020)
  • Orphazyme - Rare disease therapeutics (IPO 2017)
  • Evotec - Drug discovery platform
  • Genmab - Antibody therapeutics
  • Symphogen - Cancer antibody therapeutics

Notable Exits

  • Galecto - IPO (2020, NASDAQ: GLTO)
  • Orphazyme - IPO (2017, NASDAQ: ORPH)
  • Symphogen - Acquired (2020, acquired by Servier)
  • Santaris Pharma - Acquired (2014, acquired by Roche)
  • TopoTarget - Acquired (acquired by Onxeo)

Sources